Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Couteau

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Die Pharmazie|April 20, 2012
Comparison of two in vitro methods to evaluate the water resistance of sunscreensC Cheignon, C Couteau, A Billon-Chabaud, et al.
Bulletin Du Cancer|February 16, 2000
[High-dose chemotherapy in ovarian adenocarcinoma]J P Lotz, C Lhommé, P Pautier, et al.
Nanotechnology|January 14, 2025
Coupling of single nanodiamonds hosting SiV color centers to plasmonic double bowtie microantennasS Lindner, N Rahbany, C Pauly, et al.
British Journal of Cancer|October 3, 1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neckC Couteau, N Chouaki, S Leyvraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumorsC Couteau, M L Risse, M Ducreux, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCORT André, C Louvet, F Maindrault-Goebel, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II studyJ-Y Douillard, R Gervais, G Dabouis, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Die Pharmazie|April 20, 2012
Comparison of two in vitro methods to evaluate the water resistance of sunscreensC Cheignon, C Couteau, A Billon-Chabaud, et al.
Bulletin Du Cancer|February 16, 2000
[High-dose chemotherapy in ovarian adenocarcinoma]J P Lotz, C Lhommé, P Pautier, et al.
Nanotechnology|January 14, 2025
Coupling of single nanodiamonds hosting SiV color centers to plasmonic double bowtie microantennasS Lindner, N Rahbany, C Pauly, et al.
British Journal of Cancer|October 3, 1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neckC Couteau, N Chouaki, S Leyvraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumorsC Couteau, M L Risse, M Ducreux, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCORT André, C Louvet, F Maindrault-Goebel, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II studyJ-Y Douillard, R Gervais, G Dabouis, et al.
Pageof 5